Solventum Co. (NYSE:SOLV) Shares Bought by Clifford Capital Partners LLC

Clifford Capital Partners LLC boosted its stake in Solventum Co. (NYSE:SOLV - Free Report) by 22.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 279,479 shares of the company's stock after buying an additional 51,533 shares during the period. Solventum accounts for 3.9% of Clifford Capital Partners LLC's portfolio, making the stock its 5th biggest holding. Clifford Capital Partners LLC owned about 0.16% of Solventum worth $19,485,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SOLV. Davis Selected Advisers acquired a new stake in Solventum in the 2nd quarter valued at about $273,070,000. Nuance Investments LLC acquired a new stake in Solventum in the 2nd quarter valued at about $115,829,000. Newport Trust Company LLC acquired a new stake in Solventum in the 2nd quarter valued at about $98,976,000. Baupost Group LLC MA acquired a new stake in Solventum in the 2nd quarter valued at about $96,242,000. Finally, Magnetar Financial LLC lifted its holdings in Solventum by 2,880.8% in the 2nd quarter. Magnetar Financial LLC now owns 1,490,410 shares of the company's stock valued at $78,813,000 after acquiring an additional 1,440,410 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on SOLV shares. Stifel Nicolaus started coverage on shares of Solventum in a report on Tuesday, October 8th. They issued a "buy" rating and a $82.00 price target for the company. The Goldman Sachs Group upped their price objective on shares of Solventum from $48.00 to $54.00 and gave the company a "sell" rating in a research note on Monday, August 12th. Piper Sandler upped their price objective on shares of Solventum from $71.00 to $75.00 and gave the company a "neutral" rating in a research note on Friday, November 8th. BTIG Research began coverage on shares of Solventum in a research note on Thursday, September 5th. They set a "neutral" rating for the company. Finally, Morgan Stanley upped their price objective on shares of Solventum from $60.00 to $73.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $68.00.

Solventum Stock Performance

Shares of NYSE SOLV traded up $0.99 during midday trading on Wednesday, reaching $72.48. 702,811 shares of the company traded hands, compared to its average volume of 1,695,590. The stock's 50-day simple moving average is $70.51 and its 200-day simple moving average is $62.40. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.